Valuation: Structure Therapeutics Inc.

Market Cap 1.51B 1.35B 1.25B 1.13B 2.11B 143B 2.15B 15B 5.94B 75.15B 5.67B 5.55B 237B P/E 2026 *
-13.1x
P/E 2027 * -9.7x
Enterprise Value 544M 486M 449M 407M 761M 51.63B 773M 5.4B 2.14B 27.05B 2.04B 2B 85.29B EV / Sales 2026 *
13.1x
EV / Sales 2027 * 20,943x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day-3.37%
1 week+0.52%
Current month-32.24%
1 month-41.17%
3 months-56.86%
6 months-53.42%
Current year-69.53%
1 week 20.74
Extreme 20.7401
23.83
1 month 20.72
Extreme 20.725
35.64
Current year 20.72
Extreme 20.725
94.77
1 year 20.72
Extreme 20.725
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Conversion

Chief Technology Officer

-20,040 0.0143%
1/9/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/8/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
-3.37%+0.52%-19.70%-69.18% 1.51B
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average -0.09%+2.06%+41.30%+119.88% 38.46B
Weighted average by Cap. +0.38%+2.72%+45.76%+142.00%

Financials

2026 *2027 *
Net sales 41.67M 37.21M 34.37M 31.15M 58.28M 3.96B 59.24M 414M 164M 2.07B 156M 153M 6.53B 45.45K 40.59K 37.49K 33.98K 63.57K 4.31M 64.62K 451K 179K 2.26M 171K 167K 7.13M
Net income -314M -280M -259M -235M -439M -29.79B -446M -3.12B -1.23B -15.61B -1.18B -1.15B -49.21B -471M -421M -389M -352M -659M -44.71B -670M -4.68B -1.85B -23.43B -1.77B -1.73B -73.86B
Net Debt -967M -864M -798M -723M -1.35B -91.81B -1.38B -9.6B -3.8B -48.1B -3.63B -3.55B -152B -559M -499M -461M -418M -782M -53.08B -795M -5.55B -2.2B -27.81B -2.1B -2.05B -87.69B
Projected Income Statement - Annual - Structure Therapeutics Inc.
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
23/10/26 USD 21.19 -3.37% 798,110
22/10/26 USD 21.93 -0.36% 702,377
21/10/26 USD 22.01 -3.80% 804,460
20/10/26 USD 22.88 +3.95% 1,409,402
19/10/26 USD 22.01 +4.41% 1,312,855
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Structure Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
21.19USD
Average target price
107.29USD
Spread / Average Target
+406.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Structure Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. GPCR Stock